NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Operating Income

The latest operating income for NAMSW is $-240M as of June 2026. That compares with $-170M in the prior-year period — down 41.4% year over year. Investors often review this figure alongside NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, NAMSW's operating income moved from $-170M to $-240M — a 41.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s operating scale or balance-sheet position.

A operating income figure of $-240M for NAMSW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NAMSW's operating income ($-240M), review year-over-year change from $-170M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.